Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421233 | 1.00 | RNPEP (0.40) | RNPEPSLC7A5ALDH1A1TDP1CACNA2D1 | |
| SCHEMBL782702 | 0.88 | RNPEP (0.43) | RNPEPSLC7A5ALDH1A1TDP1CACNA2D1 | |
| SCHEMBL8463220 | 0.77 | RNPEP (0.40) | RNPEPSLC7A5ALDH1A1TDP1CACNA2D1 | |
| SCHEMBL25521057 | 0.76 | RNPEP (0.41) | RNPEPSLC7A5ANPEPERAP1 | |
| SCHEMBL21764555 | 0.76 | ENPEP (0.31) | SLC7A5 | |
| SCHEMBL20457288 | 0.76 | RNPEP (0.46) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL14191627 | 0.76 | SLC1A3 (0.37) | SLC1A3SLC1A2 | |
| SCHEMBL452363 | 0.74 | RNPEP (0.39) | RNPEPSLC7A5ALDH1A1TDP1CACNA2D1 | |
| SCHEMBL10044966 | 0.74 | RNPEP (0.39) | RNPEPSLC7A5ALDH1A1TDP1CACNA2D1 | |
| SCHEMBL15197953 | 0.74 | BLM (0.43) | ALDH1A1TDP1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035820-B2 | Compounds which inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9771392-B2 | Compounds which inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9725483-B2 | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | LIPOTEC, S.A. (ES) | 2017-08-08 | — | — | US | disclosed |
| US-20160220693-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9272052-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEATTLE GENETICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150140046-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150104485-A1 | COMPOUNDS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150098989-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-04-09 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110300199-A1 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR SCALP AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LIPOTEC, S.A. (ES) | 2011-12-08 | — | — | US | disclosed |
| US-20110195102-A1 | PEPTIDES USEFUL IN THE TREATMENT AND/OR CARE OF SKIN, MUCOUS MEMBRANES, SCALP AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LIPOTEC, S.A. (ES) | 2011-08-11 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110110936-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110052519-A1 | PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS | PUIG, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098989-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | RNPEP 1233/4885SLC7A5 558/4885ALDH1A1 2398/4885 |
| US-10035820-B2 | Compounds which inhibit neuronal exocytosis | SLC18A2, SLC18A1, ATP6V1B2 | RNPEP 1233/4885SLC7A5 558/4885ALDH1A1 2398/4885 |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | TNFRSF1A, TNFSF10, TNFRSF9 | RNPEP 2484/4885SLC7A5 3767/4885ALDH1A1 2427/4885 |
| US-20160220693-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | RNPEP 1904/4885SLC7A5 481/4885ALDH1A1 3563/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | RNPEP 1380/4885SLC7A5 2995/4885ALDH1A1 4261/4885 |
| US-20110052519-A1 | PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS | POLR1C, NGLY1, SSTR4 | RNPEP 52/4885SLC7A5 2552/4885ALDH1A1 1420/4885 |
| US-20110110936-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | CD2BP2, UACA, COPG2 | RNPEP 924/4885SLC7A5 3458/4885ALDH1A1 4609/4885 |
| US-20110195102-A1 | PEPTIDES USEFUL IN THE TREATMENT AND/OR CARE OF SKIN, MUCOUS MEMBRANES, SCALP AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | CUTA, MC1R, NGLY1 | RNPEP 172/4885SLC7A5 2324/4885ALDH1A1 1616/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | RNPEP 58/4885SLC7A5 1233/4885ALDH1A1 4866/4885 |
| US-20150140046-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | RNPEP 1370/4885SLC7A5 723/4885ALDH1A1 2751/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | RNPEP 2203/4885SLC7A5 2176/4885ALDH1A1 2989/4885 |
| US-20150104485-A1 | COMPOUNDS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | MC1R, TYR, MC3R | RNPEP 2263/4885SLC7A5 1915/4885ALDH1A1 1761/4885 |
| US-20110300199-A1 | PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR SCALP AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | NGLY1, VIP, CUTA | RNPEP 192/4885SLC7A5 2981/4885ALDH1A1 4395/4885 |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | RNPEP 244/4885SLC7A5 2130/4885ALDH1A1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.